Wang D S, Zhang H Q, Zhang B, Yuan Z B, Yu Z K, Yang T, Zhang S Q, Liu Y, Jia X X
Department of Neurosurgery, Second Affiliated Hospital of Dalian Medical University, Dalian, China.
Genet Mol Res. 2016 Mar 24;15(1):gmr7453. doi: 10.4238/gmr.15017453.
Many studies have shown that microRNA (miR)-133 functions as a tumor suppressor in a variety of metastatic cancers, including breast cancer, gastric cancer, and liver fibrosis. However, the influence of miR-133 on pituitary tumor malignancy has not yet been reported. The purpose of this study was to explore the role of miR-133 in pituitary tumor cell migration and invasive ability and the molecular mechanisms involved. Our findings suggest that in pituitary adenoma cell lines, through direct targeting and negative control of forkhead box C1 (FOXC1), miR-133 can inhibit pituitary adenoma cell migration and invasion. In addition, epithelial-to-mesenchymal transition can be induced by miR-133. Additionally, a negative correlation was found between FOXC1 and miR-133 expression when comparing their expression levels between cancerous tissue and adjacent normal tissue. This suggests that miR-133 can inhibit cell migration and invasion by directly targeting FOXC1, implying that miR-133 could be a potential therapeutic target for treatment of invasive pituitary adenoma.
许多研究表明,微小RNA(miR)-133在包括乳腺癌、胃癌和肝纤维化在内的多种转移性癌症中发挥肿瘤抑制作用。然而,miR-133对垂体肿瘤恶性程度的影响尚未见报道。本研究的目的是探讨miR-133在垂体肿瘤细胞迁移和侵袭能力中的作用及其相关分子机制。我们的研究结果表明,在垂体腺瘤细胞系中,miR-133通过直接靶向并负调控叉头框C1(FOXC1),可抑制垂体腺瘤细胞的迁移和侵袭。此外,miR-133可诱导上皮-间质转化。另外,在癌组织和相邻正常组织中比较FOXC1和miR-133的表达水平时,发现二者呈负相关。这表明miR-133可通过直接靶向FOXC1抑制细胞迁移和侵袭,提示miR-133可能是侵袭性垂体腺瘤治疗的潜在靶点。